Adherence and persistence: Impact on outcomes and health care resources

Bone

Volumn 38, Issue 2 SUPPL., 2006, Pages 18-21

  Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Adherence; Bisphosphonates; Osteoporosis; Persistence

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PHOSPHATE; UNCLASSIFIED DRUG;

BONE DENSITY; BONE TURNOVER; DOCTOR PATIENT RELATION; FRACTURE; HEALTH CARE MANAGEMENT; HUMAN; INTERPERSONAL COMMUNICATION; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT FAILURE;

EID: 31744447638     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.11.013     Document Type: Article

References (25)

1. J.C. Sung, M.B. Nichol, F. Venturini, K.L. Bailey, J.S. McCombs, and M. Cody Factors affecting patient compliance with antihyperlipidemic medications in an HMO population Am. J. Manag. Care 4 1998 1421 1430
2. J.A. Rizzo, and W.R. Simons Variations in compliance among hypertensive patients by drug class: implications for health care costs Clin. Ther. 19 1997 1446 1457
3. A. Giuffrida, and D.J. Torgerson Should we pay the patient? Review of financial incentives to enhance patient compliance BMJ 315 1997 703 707
4. R.A. Yood, S. Emani, J.I. Reed, B.E. Lewis, M. Charpentier, and E. Lydick Compliance with pharmacologic therapy for osteoporosis Osteoporos. Int. 14 2003 965 968
5. J.S. McCombs, P. Thiebaud, C. McLaughlin-Miley, and J. Shi Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 2004 271 287
6. N.H. Miller Compliance with treatment regimens in chronic asymptomatic diseases Am. J. Med. 102 1997 43 49
7. W.S. Bond, and D.A. Hussar Detection methods and strategies for improving medication compliance Am. J. Hosp. Pharm. 48 1991 1978 1988
8. R. Eastell, P. Gamero, B. Vrijens, L. van de Langerjit, H.A.P. Pols, and J.D. Ringe Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study Calcif. Tissue Int. 72 2003 297 408
9. J. Finigan, P.R. Bainbridge, and R. Eastell Adherence to osteoporosis therapies Osteoporos. Int. 12 2001 S48 S49 [Abstract P110]
10. J.J. Caro, K.J. Ishak, K.F. Huybrechts, G. Raggio, and C. Naujoks The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos. Int. 15 2004 1003 1008
11. General Practitioners Research Database, UK. Available at: http://www.gprd.com/home/. Accessed May 4, 2005.
12. C. Lombas, C. Hakim, and J.R. Zanchetta Compliance with alendronate treatment in an osteoporosis clinic J. Bone Miner. Res. 16 Suppl 1 2001 S529 [Abstract M406]
13. A.N. Tosteson, M.R. Grove, C.S. Hammond, M.M. Moncur, G.T. Ray, and G.M. Hebert Early discontinuation of treatment for osteoporosis Am. J. Med. 115 2003 209 216
14. F. Bandeira, M. Kayath, J. Marqus-Neto, S. Ragi, J. Danovski, and S. Radominski Patients' clinical features and compliance associated with raloxifene or alendronate after a 6-month observational Brazilian study J. Bone Miner. Res. 18 Suppl 2 2003 S379 [Abstract M352]
15. R.J. Sebaldt, L.G. Shane, B.Z. Pham, R.J. Cook, L. Thabane, and A. Petrie Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis J. Bone Miner. Res. 19 Suppl 1 2004 S445 [Abstract M423]
16. L.B. Tankó, U. Mouritzen, H.J. Lehmann, L. Warming, A. Moelgaard, and S. Christgau Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens Bone 32 2003 687 693
17. E. Bronder, and A. Klimpel Unused drugs returned to the pharmacy-New data Int. J. Clin. Pharmacol. Ther. 39 2001 480 483
18. S.D. Sullivan, D.H. Kreling, and T.K. Hazlet Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate J. Res. Pharm. Econ. 2 1990 19 33
19. N. Col, J.E. Fanale, and P. Kronholm The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly Arch. Intern. Med. 150 1990 841 845
20. J.S. Berg, J. Dischler, D.J. Wagner, J.J. Raia, and N. Palmer-Shevlin Medication compliance: a healthcare problem Ann. Pharmacother. 27 1993 S5 S24 [Suppl]
21. E.W. Seely, A. Ravnikar, and B.L. McClung Patient-provider decisions about long-term therapy Am. J. Manag. Care 4 2 Suppl 1998
22. S.R. Eastaugh, and M.E. Hatcher Improving compliance among hypertensives: a triage criterion with cost-benefit implications Med. Care 20 1982 1001 1017
23. J.A. Clowes, N.F. Peel, and R. Eastell The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J. Clin. Endocrinol. Metab. 89 2004 1117 1123
24. A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin. Ther. 23 2001 1296 1310
25. B. Hamilton, K. McCoy, and H. Taggart Tolerability and compliance with risedronate in clinical practice Osteoporos. Int. 14 2003 259 262